Margaret A. Tempero, MD
Although pancreatic cancer has not seen the rapid emergence of new agents occurring in other oncology fields, more widespread utilization of genetic testing may offer investigators a leg up in the fight against the disease, said Margaret A. Tempero, MD.
Arguably the biggest advancement made in recent years has been with the introduction of FOLFIRINOX in the adjuvant setting. Findings from the PRODIGE 24/CCTG PA.6 trial showed that the median overall survival (OS) in patients treated with modified FOLFIRINOX (mFOLFIRINOX) was 54.4 months versus 35.0 months with gemcitabine, translating to a 36% reduction in the risk of death (HR, 0.64; 95% CI, 0.48-0.86; P
= .003). Median disease-free survival (DFS) was 21.6 months versus 12.8 months, also in favor of mFOLFIRINOX. Moreover, the 3-year DFS rates were 39.7% versus 21.4% with mFOLFIRINOX versus gemcitabine, respectively, according to data presented at the 2018 ASCO Annual Meeting.
... to read the full story